Conference Call with Kiri Industries Management and Analysts on Q3FY25 Performance and Outlook. Listen to the full earnings transcript.
Specialty Chemicals company Kiri Industries announced Q3FY25 results Consolidated revenues were Rs 281.25 crore, reflecting an 27% YoY growth and a 3% QoQ rise. Consolidated EBIDTA for Q3FY25 was Rs -8.39 crore reflecting negative earnings by 2.8% QoQ due to higher expenditure towards legal fees pertaining to DyStar Case. Kiri’s standalone revenue for Q3FY25 was Rs156.38 crore marking an increase by 8% YoY and 11% QoQ. The Standalone EBIDTA for Q3FY25 was positive Rs 37.40 crore. Result PDF
Specialty Chemicals company Kiri Industries announced H1FY25 & Q2FY25 results Standalone Financial Highlights: Standalone revenue for Q2FY25 was Rs 145.52 crore marking a -4% YoY change and -13% QoQ. Standalone EBIDTA for Q2FY25 was -2.81 crore. The Material Margin has increased by 5.3% QoQ and 12.4% YoY. PBT: Rs -22.12 crore compared to Rs -2.76 crore during Q2FY24. Consolidated Financial Highlights: Consolidated revenue for H1FY25 amounted to Rs 537.39 crore, marking a 17% YoY increase. Consolidated revenues were Rs 272.23 crore, reflecting an 18% YoY growth and a 3% QoQ rise. Consolidated EBIDTA for H1FY25 amounted to Rs 40.01 crore a significant improvement from negative EBIDTA in the H1FY24. Consolidated EBIDTA for Q2FY25 was Rs 21.94 crore reflecting 21% QoQ increase. Result PDF
Conference Call with Kiri Industries Management and Analysts on Q4FY24 Performance and Outlook. Listen to the full earnings transcript.